|
March 2002 (v02-n03) |
|
- Main Story - pgs. 1-15 Genta Corporation (NASDAQ:GNTA)
- Macro Market Commentary - pgs. 16-17
- News Briefs - pg. 18
- NIBM Model Portfolio & Updates - pgs. 19-22
|
 |
|
| This month's Main Story is on Genta
Corporation. Genta is a leading developer of antisense technology targeting BCL-2 -- a
substance overexpressed on 70% of cancers that enables them to avoid natural apoptosis, or
programmed cell death. Clinical trials have shown Genta's lead product, Genasense, is
capable of down-regulating BCL-2, enhancing the effectiveness of a variety of
already-approved chemotherapy drugs. The company also has aptamer and antiandrogenic
compounds in development. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Genta
- Introduction
- Table: Basic Facts
- Table: Drug Pipeline
- Disclosure
- Table: Financing Events
- Table: Licensing/Acquisition Events
Antisense = anti-cancer
- New treatment approaches & apoptosis
- Table: Some companies targeting BCL-2 or other apoptosis
targets
- Antisense treatments
- Table: Companies with antisense treatments in clinical trials
Genasense: The BCL-2 Antisense Therapy
- Table: Genasense indications, clinical phase, and research
protocols
- Breadth of utility
- Table: Incidence and Prevalence
- Table: Paired Treatments
Ganite
- Table: Intravenous gallium vs. oral gallium
- Sidebar: How gallium (hypothetically) works
Androgenics
Decoy Aptamers
Table:Comparison between aptamers and MAbs
NIBM's Genta Coverage
What Can Go Wrong
Table: Important investor milestones
- Macro Market Commentary
- News Briefs
- SpaceLabs investors finally get their merger
- AVI Biopharma raises $22M in private sale
- Biopure sinking fast
- NIBM Model Portfolio and Updates
- AltaRex
- Nabi Biopharmaceuticals
- Dendreon
- Targeted Genetics
- Titan Pharmaceuticals
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
